By Health In Five Writer
Dr Reddys Laboratories Ltd announced the launch of Remdesivir, meant for treatment of COVID-19 patients, under a brand name ‘Redyx’ in India. Remdesivir is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences.
It is administered via injection into a vein. Remdesivir is being tested as a treatment for COVID‑19, and has been authorized for emergency use in the US, India, Singapore and approved for use in Japan, the European Union, and Australia for people with severe symptoms.
According to a press release from Dr Reddys Laboratories, the launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr Reddys the right to register, manufacture and sell Remdesivir – a potential treatment for Covid-19 – in 127 countries including India.
Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalized with severe symptoms. “Dr Reddy’s Redyx is available in strength of 100 mg vial,” the statement read.
“We will continue our efforts to develop products that address significant unmet needs of patients. The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India,” Chief Executive Officer of Branded Markets (India and Emerging Markets), Dr Reddys Laboratories, M V Ramana said.
